CareDx Reports 39% Revenue Growth in Q3 2026, Driven by Transplant Testing
What happened
CareDx, Inc. reported third-quarter 2026 revenue of $139 million, marking a 39% increase from the previous year and a 6% sequential rise. Testing-services revenue reached $119 million, representing 86% of total revenue. The company also reported 75,900 tests completed during the quarter, a 51% increase year over year.
From tickerreport.com
Why it matters
The growth was driven by the transplant business, which saw volume rise 21% year over year, and the addition of Specialty Oncology testing following the acquisition of Naveris. Adjusted EBITDA doubled year over year to $30 million, demonstrating improved profitability.
From tickerreport.com
Who's involved
- CareDx, IncMedical transplant company that reported Q3 2026 earnings
- EpicHealthcare software company whose platform CareDx is utilizing
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- CareDx, IncSpeculative
The company might see increased revenue and operating cash flow due to strong testing volume growth.